Kuria Therapeutics Selected to Present at 2023 Texas Life Science Forum
Kuria's Chief Operating Officer, Dr. Misty Stevens, to present corporate overview and review Kuria's ophthalmic development plans
Kuria Therapeutics, a pharmaceutical company developing a platform of novel Nrf2 activators for ophthalmic disease, has been selected for participation in the Texas Life Science Forum in Houston. Kuria's Chief Operating Officer, Dr. Misty Stevens, will provide a platform presentation to discuss Kuria's work to develop novel Nrf2 activators to Power Sight in blinding diseases of the retina and cornea. Dr. Stevens will also be holding individual investor meetings during Investor Office Hours at the conference. Dr. Stevens' live presentation will occur on November 7 at the meeting at Rice University. Register for the forum at https://txlifescienceforum.org.
About Kuria Therapeutics, Inc.: Kuria Therapeutics, Inc. is a US-based pharmaceutical company dedicated to the development of novel therapeutics for ophthalmic disease. We are a team of seasoned life science executives and entrepreneurs with decades of experience in building biotechnology companies, running complex multi-national development programs, managing alliances with partners, and building relationships with clinicians, investors, vendors, and patient groups. For more information, visit www.kuriatx.com.
Contacts Investor Relations and Media Kuria Therapeutics: Corporate Communication